These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 8631603

  • 1. Biochemical characterization of a mitomycin C-resistant human bladder cancer cell line.
    Singh SV, Scalamogna D, Xia H, O'Toole S, Roy D, Emerson EO, Gupta V, Zaren HA.
    Int J Cancer; 1996 Mar 15; 65(6):852-7. PubMed ID: 8631603
    [Abstract] [Full Text] [Related]

  • 2. Characterization of a human bladder cancer cell line selected for resistance to mitomycin C.
    Xu BH, Gupta V, Singh SV.
    Int J Cancer; 1994 Sep 01; 58(5):686-92. PubMed ID: 8077054
    [Abstract] [Full Text] [Related]

  • 3. [Mechanism of resistance to mitomycin C in a human bladder cancer cell line].
    Xu B, Sun Y, Singh SV.
    Zhonghua Zhong Liu Za Zhi; 1995 Sep 01; 17(5):343-6. PubMed ID: 8697971
    [Abstract] [Full Text] [Related]

  • 4. Mechanism of cross-resistance to cisplatin in a mitomycin C-resistant human bladder cancer cell line.
    Singh SV, Xu BH, Jani JP, Emerson EO, Backes MG, Rihn C, Scalamogna D, Stemmler N, Specht S, Blanock K.
    Int J Cancer; 1995 May 04; 61(3):431-6. PubMed ID: 7729958
    [Abstract] [Full Text] [Related]

  • 5. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance.
    Xu BH, Gupta V, Singh SV.
    Arch Biochem Biophys; 1994 Jan 04; 308(1):164-70. PubMed ID: 8311448
    [Abstract] [Full Text] [Related]

  • 6. Characterization of a BMS-181174-resistant human bladder cancer cell line.
    Xia H, Bleicher RJ, Hu X, Srivastava SK, Gupta V, Zaren HA, Singh SV.
    Br J Cancer; 1997 Jan 04; 76(4):461-6. PubMed ID: 9275022
    [Abstract] [Full Text] [Related]

  • 7. Mechanism of increased sensitivity to etoposide in a mitomycin C-resistant human bladder cancer cell line.
    Xia H, Bleicher RJ, Gupta V, Zaren HA, Singh SV.
    Int J Cancer; 1997 Mar 04; 70(5):606-11. PubMed ID: 9052763
    [Abstract] [Full Text] [Related]

  • 8. Biochemical mechanism of cross-resistance to paclitaxel in a mitomycin c-resistant human bladder cancer cell line.
    Bleicher RJ, Xia H, Zaren HA, Singh SV.
    Cancer Lett; 2000 Mar 31; 150(2):129-35. PubMed ID: 10704734
    [Abstract] [Full Text] [Related]

  • 9. Characterization of a human bladder cancer cell line selected for resistance to BMY 25067, a novel analogue of mitomycin C.
    Singh SV, Xu BH, Gupta V, Emerson EO, Zaren HA, Jani JP.
    Cancer Lett; 1995 Aug 16; 95(1-2):49-56. PubMed ID: 7656243
    [Abstract] [Full Text] [Related]

  • 10. The importance of DT-diaphorase in mitomycin C resistance in human colon cancer cell lines.
    Lambert PA, Kang Y, Greaves B, Perry RR.
    J Surg Res; 1998 Dec 16; 80(2):177-81. PubMed ID: 9878310
    [Abstract] [Full Text] [Related]

  • 11. Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors.
    Gan Y, Mo Y, Kalns JE, Lu J, Danenberg K, Danenberg P, Wientjes MG, Au JL.
    Clin Cancer Res; 2001 May 16; 7(5):1313-9. PubMed ID: 11350900
    [Abstract] [Full Text] [Related]

  • 12. Mechanism of differential sensitivity of human bladder cancer cells to mitomycin C and its analogue.
    Xu BH, Gupta V, Singh SV.
    Br J Cancer; 1994 Feb 16; 69(2):242-6. PubMed ID: 8297721
    [Abstract] [Full Text] [Related]

  • 13. [DT-diaphorase].
    Mikami K, Shirakusa T, Tsuruo T.
    Gan To Kagaku Ryoho; 1997 Sep 16; 24(11):1606-10. PubMed ID: 9309161
    [Abstract] [Full Text] [Related]

  • 14. Isolation and characterization of a mitomycin C-resistant variant of human colon carcinoma HT-29 cells.
    Lee JH, Naito M, Nakajima M, Tsuruo T.
    Cancer Chemother Pharmacol; 1993 Sep 16; 33(3):215-20. PubMed ID: 7505723
    [Abstract] [Full Text] [Related]

  • 15. Molecular targeting of mitomycin C chemotherapy.
    Nishiyama M, Suzuki K, Kumazaki T, Yamamoto W, Toge T, Okamura T, Kurisu K.
    Int J Cancer; 1997 Aug 07; 72(4):649-56. PubMed ID: 9259406
    [Abstract] [Full Text] [Related]

  • 16. Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development.
    Phillips RM, Burger AM, Loadman PM, Jarrett CM, Swaine DJ, Fiebig HH.
    Cancer Res; 2000 Nov 15; 60(22):6384-90. PubMed ID: 11103802
    [Abstract] [Full Text] [Related]

  • 17. Investigation of sequential mitomycin C and photodynamic therapy in a mitomycin-resistant bladder cancer cell-line model.
    French AJ, Datta SN, Allman R, Matthews PN.
    BJU Int; 2004 Jan 15; 93(1):156-61. PubMed ID: 14678389
    [Abstract] [Full Text] [Related]

  • 18. Modulation of mitomycin C resistance by glutathione transferase inhibitor ethacrynic acid.
    Singh SV, Xu BH, Maurya AK, Mian AM.
    Biochim Biophys Acta; 1992 Nov 17; 1137(3):257-63. PubMed ID: 1445927
    [Abstract] [Full Text] [Related]

  • 19. Lack of a role of glutathione in cellular nonenzymatic activation of BMS-181174, a novel analogue of mitomycin C.
    Xia H, Pinto T, Hu X, Benson PJ, Zaren HA, Gupta V, Singh S.
    Cancer Res; 1996 Aug 01; 56(15):3495-8. PubMed ID: 8758917
    [Abstract] [Full Text] [Related]

  • 20. Nonenzymatic reductive activation of 7-N-((2-([2-(gamma-L-glutamylamino)ethyl]dithio)ethyl))mitomycin C by thiol molecules: a novel mitomycin C derivative effective on mitomycin C-resistant tumor cells.
    Lee JH, Naito M, Tsuruo T.
    Cancer Res; 1994 May 01; 54(9):2398-403. PubMed ID: 8162587
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.